Glofitamab is a bispecific antibody with a T – cell-based immunotherapy. 

It simultaneously binds to CD20 positive target B cells and CD3 positive T cells.

It is a biclonal protein that works by simultaneously binding CD20 positive target B cells and CD3positive T cells, bringing the cells close together and result in a T cell mediated lymphoma killing. 

It has a full-length IgG like structure that allows cyclical administration either intravenously or subcutaneously, at intervals 1-4 weeks.

Patients with diffuse large B cell lymphoma (DLBCL) typically exhibit expression of proteins CD20 on the surface of their tumor cells. 

Glofitamab gauges T cells to seek out and destroy CD 20 positive lymphphoma Cells in DLBCL. 

Leave a Reply

Your email address will not be published. Required fields are marked *